APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
"This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "AML is an aggressive disease and relapsed/refractory patients have an extremely poor prognosis. We look forward to initiating our Phase 3 bridging study this year and working with the CDE on a potentially accelerated clinical development program to address this important patient need."
In September 2020, the NMPA CDE granted Investigational New Drug (IND) approval for APL-106 enabling the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML.
The BTD is part of the revised Drug Registration Regulation that became effective in July 2020 in China. The BTD is designed to expedite the development and review of therapies that are being developed for treatment of serious diseases for which there is no existing treatment or where preliminary evidence indicates significant advantages of the therapy over available treatment options(1).
About Uproleselan (APL-106)
Discovered and developed by GlycoMimetics, uproleselan (APL-106) is a late clinical-stage, potentially first-in-class, targeted inhibitor of E-selectin. Uproleselan (yoo' pro le' sel an) is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to uproleselan for treatment of adults with relapsed or refractory AML. Apollomics licensed APL-106 from GlycoMimetics in January 2020 to develop and commercialize APL-106 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.
About Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. It is an aggressive disease that causes the bone marrow to produce immature cells that are unable to carry out their normal function and develop into leukemic white blood cells called myeloblasts. In the U.S., there are approximately 20,000 new cases of AML each year and a 5-year survival rate of 28.7%(2). The annual incidence of new cases of AML in China is 21,600, and relapsed/refractory AML has an extremely poor prognosis(3).
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage clinical development programs and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements, including those relating to the planned or potential clinical development of uproleselan and engagement with regulatory authorities, as well as the potential benefits and impact of the product candidate. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements as they relate to GlycoMimetics, as well as other risks facing GlycoMimetics, please see the risk factors described in the GlycoMimetics annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2020, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.
(1) China Drug Registration Regulation: http://www.gov.cn/gongbao/content/2020/content_5512563.htm (2) National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program (3) Yang Xiaofeng, Zhang Sufen, Zhang Qingyuan. Practical Therapeutics of Hematological Diseases[M]. Military Medical Science Press, 2008.
Apollomics Contact Information:
Investor Contact: Wilson W. Cheung Chief Financial Officer (650) 209-4436 wcheung@apollomicsinc.com
China Media Contact: Porda Havas International Finance Communications Group Kelly Fung General Manager (852) 3150-6763 kelly.fung@pordahavas.com
Phoenix Fung Assistant Vice President (852) 3150-6773 phoenix.fung@pordahavas.com
U.S. Media Contact: Remy Bernarda Corporate Communications (415) 203-6386 remy.bernarda@apollomicsinc.com
GlycoMimetics Contact Information:
Investor Contact: Shari Annes (650) 888-0902 sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira (410) 299-3310 jamielacey@presscommpr.com
Source: Apollomics, Inc. Sectors: BioTech
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Related Press Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq | March 30 2023 20:29 JST | | Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer | July 26 2022 09:17 JST | | Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 | January 12 2022 09:25 JST | | Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group | January 04 2022 10:10 JST | | Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia | November 22 2021 10:40 JST | | Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial | October 01 2021 10:00 JST | | Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 | August 10 2021 11:53 JST | | APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH | May 20 2021 13:36 JST | | Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer | March 09 2021 10:35 JST | | Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China | March 04 2021 11:30 JST | | More Press release >> |
Latest Press Release
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning May 17, 2024 14:03 JST
| NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud May 17, 2024 11:19 JST
| Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles May 15, 2024 14:30 JST
| Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 15, 2024 11:19 JST
| SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern May 14, 2024 21:54 JST
| DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot May 14, 2024 11:02 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings May 13, 2024 18:32 JST
| Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures May 13, 2024 17:06 JST
| Ogier and TOYOTA GAZOO Racing triumph again May 13, 2024 14:36 JST
| Spa points haul for TOYOTA GAZOO Racing May 13, 2024 13:56 JST
| DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion May 10, 2024 18:13 JST
| Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku" May 10, 2024 12:20 JST
| Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024 May 09, 2024 20:39 JST
| Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore May 09, 2024 19:00 JST
| Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India May 09, 2024 14:13 JST
| Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning May 09, 2024 10:41 JST
| Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance May 08, 2024 14:27 JST
| Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers May 08, 2024 12:00 JST
| NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement May 08, 2024 10:24 JST
| ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions May 08, 2024 08:52 JST
|
More Latest Release >>
|